CME in Minutes: Education in Oncology & Hematology - podcast cover

CME in Minutes: Education in Oncology & Hematology

Answers in CMEanswersincme.com
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Last refreshed:
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Download Metacast podcast app
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episodes

The Promise of Oral Therapy for HER2-Mutated NSCLC: Unlocking New Treatment Opportunities With a Familiar Target

Please visit answersincme.com/860/IME_2025_00012595-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John V. Heymach, MD, PhD; and Mark Awad, MD, PhD. In this activity, experts in oncology discuss the role of dual and HER2-selective oral tyrosine kinase inhibitors in patients with HER2-mutated non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Specify how TKIs may address...

Jun 05, 20261 hr 14 min

Clinical Pearls for Subcutaneous Delivery: Optimizing Anti-CD38 Use in Multiple Myeloma

Please visit answersincme.com/860/2026-MC-001665-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ajai Chari, MD; Caitlin Costello, MD; and Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO. In this activity, experts in multiple myeloma (MM) discuss the therapeutic rationale, clinical data, and practical integration of subcutaneous anti-CD38 therapies to optimize care for patients with MM. Upon completion of this ac...

Jun 03, 20261 hr 4 min

Expanding the Use of HER2-Directed ADCs Into Early-Stage Breast Cancer: Multidisciplinary Conversations on (Neo)Adjuvant Care

Please visit answersincme.com/860/101385133-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter A. Fasching, MD; Michael Gnant, MD, FACS; and Cristina Saura Manich, MD, PhD. In this activity, experts in breast cancer discuss new evidence in neoadjuvant and adjuvant care of early disease. Upon completion of this activity, participants should be better able to: Describe multidisciplinary viewpoints on the role that HER2...

May 20, 20261 hr 1 min

Personalized Treatment Strategies With First-Line Immunotherapy-Based Regimens in Advanced Colorectal Cancer and Biliary Tract Cancer

Please visit answersincme.com/PNQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rachel Goodwin, MSc, MD, FRCPC; and Vincent Tam, MD. In this activity, experts in colorectal cancer and biliary tract cancer discuss first-line immunotherapy considerations. Upon completion of this activity, participants should be better able to: Evaluate the clinical profiles of first-line immunotherapy-based regimens for the treatment of pat...

May 18, 202624 min

KIT D816V in Focus: Optimizing Diagnosis and TKI Therapy in Advanced Systemic Mastocytosis

Please visit answersincme.com/CKX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prithviraj Bose, MD. In this activity, an expert in hematology discusses the role of current and emerging treatment options for patients living with advanced systemic mastocytosis. Upon completion of this activity, participants should be better able to: Identify prognostic features of advanced systemic mastocytosis (AdvSM) that guide diagnosis...

May 15, 202614 min

Cracking the Code of KRAS-Mutant NSCLC: Evidence for Emerging Therapies in First-Line Settings

Please visit answersincme.com/GYB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Pasi A. Jänne, MD, PhD, FASCO. In this activity, an expert in oncology discusses the role of emerging KRAS inhibitors in the treatment paradigm for non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Explain the rationale for targeted therapy in previously untreated patients with KRAS-mu...

May 13, 202614 min

Sebastien J. Hotte, MD, FRCPC - An Integrated Approach to Optimizing Radioligand Therapy and Bone Health Management in mCRPC

Please visit answersincme.com/NZU860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sebastien J. Hotte, MD, FRCPC. In this activity, an expert in oncology discusses radioligand therapy for metastatic castration-resistant prostate cancer. Upon completion of this activity, participants should be better able to: Evaluate how the current guidelines and evidence may inform the sequencing of radioligand therapies in patients with m...

May 12, 202617 min

30-Minute Power Briefing: ICIs in Frontline Advanced Classical Hodgkin Lymphoma—What’s New and What’s Now?

Please visit answersincme.com/860/102771731-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sairah Ahmed, MD; and Sharon Marie Castellino, MD, MSc. In this activity, experts in Hodgkin lymphoma discuss unmet needs and emerging data in the treatment of classical HL. Upon completion of this activity, participants should be better able to: Explain the rationale for investigating ICI-based regimens for previously untreated ...

May 08, 202636 min

From Burden to Breakthrough: The Rise of KIT D816V-Selective Therapy in Indolent Systemic Mastocytosis

Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize the impacts of indolent systemic mastocytosis (ISM) on patients’ quality of life; Discuss the clinic...

May 05, 202614 min

Guidance on Menopause-Related Vasomotor Symptom Management: A Focus on Neurokinin-Targeted Treatment Options

Please visit answersincme.com/NYR860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jill Liss, MD, MSCP; Denise Black, MD, FRCSC; and Danielle Covarrubias. In this activity, experts in women’s health, joined by a patient advocate, discuss the burden of menopause-related vasomotor symptoms (VMS) and novel management strategies. Upon completion of this activity, participants should be better able to: Identify the impact and bur...

Apr 30, 202627 min

From Evidence to Practice: Where Do BCMA Bispecific Antibodies and Anti-CD38 mAb Combinations Fit Into Community Care for RRMM?

Please visit answersincme.com/860/102653681-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jesus Berdeja, MD; and Saad Z. Usmani, MD, MBA, FACP, FASCO. In this activity, experts in multiple myeloma (MM) discuss how BCMA bispecific antibody (BsAb)–anti-CD38 monoclonal antibody combinations fit into the treatment paradigm for patients with relapsed/refractory MM. Upon completion of this activity, participants should be b...

Apr 27, 20261 hr 4 min

Evolving Care in B-ALL: From Questions to Answers on the Role of CD19 Bispecific T-Cell Engagers

Please visit answersincme.com/AXB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Bijal Shah, MD, MS. In this activity, an expert in oncology discusses B-cell acute lymphoblastic leukemia. Upon completion of this activity, participants should be better able to: Describe the rationale for the development of novel dual CD19 x CD3-targeting bispecific antibodies for patients with relapsed/refractory; B-cell acute lymphoblastic...

Apr 24, 202620 min

Navigating Urologic Cancer Care Across the Map: Getting up to Speed on the Latest Systemic Therapies for Renal Cell Carcinoma and Advanced Urothelial Carcinoma

Please visit answersincme.com/860/240201307-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aly-Khan A. Lalani, MD, FRCPC; Normand Blais, MD, MSc; and Dorothy Lo, MD, FRCP(C), MHSc, PhD. In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss evidence-based strategies for integrating the latest systemic therapies into practice to optimize outcomes for patient...

Apr 23, 20261 hr 10 min

Management of High-Risk CLL in the BTK Inhibitor Era: Frontline to Double-Refractory Disease

Please visit answersincme.com/860/240201373-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Julie Stakiw, MD, FRCPC; and Constantine S. Tam, MBBS, MD. In this activity, experts in chronic lymphocytic leukemia (CLL) use case examples to discuss treatment management of high-risk CLL in both the frontline and relapsed/refractory settings. Upon completion of this activity, participants should be better able to: Identify hig...

Apr 20, 20261 hr 2 min

Navigating Urologic Cancer Care Across the Map: Getting up to Speed on the Latest Systemic Therapies for Renal Cell Carcinoma and Advanced Urothelial Carcinoma

Please visit answersincme.com/860/240201307-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aly-Khan A. Lalani, MD, FRCPC; Normand Blais, MD, MSc; Krista Noonan, BSc, MD, FRCPC and Eleftherios Soleas, PhD In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss evidence-based strategies for integrating the latest systemic therapies into practice to optimize ou...

Apr 17, 20261 hr 11 min

The ON Switch: Overcoming KRAS Resistance Using Next-Generation Targeted Inhibitors in Advanced NSCLC

Please visit answersincme.com/AZB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Salman R. Punekar, MD, MSc. In this activity, an expert in the management of non–small-cell lung cancer (NSCLC) discusses the unmet treatment needs with current RAS(OFF) inhibitors and the potential role for emerging next-generation RAS(ON) inhibitors in KRAS-mutant NSCLC. Upon completion of this activity, participants should be better able to...

Apr 15, 202613 min

Navigating Urologic Cancer Care Across the Map: Getting up to Speed on the Latest Systemic Therapies for Renal Cell Carcinoma and Advanced Urothelial Carcinoma

Please visit answersincme.com/860/240201307-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Normand Blais, MD, MSc; Aly-Khan A. Lalani, MD, FRCPC; Wassim Kassouf, MD; and Eleftherios Soleas, PhD. In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss evidence-based strategies for integrating the latest systemic therapies into practice to optimize outcomes fo...

Apr 10, 20261 hr 10 min

The Next Wave of CAR T Innovation for RRMM: Insights Into Emerging GPRC5D-Directed CAR T-Cell Therapies

Please visit answersincme.com/KTB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Krina Patel, MD, MSc. In this activity, Krina Patel, MD, MSc, an expert in multiple myeloma, discusses emerging GPRC5D CAR T-cell therapies in relapse/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Describe the clinical rationale for the use of emerging GPRC5D CAR T-cell therapy in the con...

Apr 10, 202615 min

Bridging Clinic and OR: A Dialogue on the Emerging Role of Neoadjuvant HER2-Directed ADCs in HER2+ Breast Cancer

Please visit answersincme.com/FBF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Paolo Tarantino, MD, PhD and Christopher Vetter, MD, MSc, FACS. In this activity, experts in breast cancer discuss the role of neoadjuvant human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugates in HER2+ early-stage breast cancer. Upon completion of this activity, participants should be better able to: Recognize the r...

Apr 08, 202625 min

Survivorship Strategies for Patients on First-Line HER2+ mBC Maintenance Therapies: Practical Guidance on Monitoring and AE Management

Please visit answersincme.com/860/100850799-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Jane Meisel, MD, FASCO. In this activity, experts in breast cancer discuss practical approaches to optimize survivorship and patient care for patients with HER2-positive metastatic breast cancer who are on first-line maintenance treatment. Upon completion of this activity, participants s...

Apr 01, 202630 min

When Form Maximizes Function: Examining the Role of Subcutaneous Immune Checkpoint Inhibitors in Oncology Practice

Please visit answersincme.com/KWA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Benjamin Levy, MD, FASCO. In this activity, an expert in oncology discusses the use of subcutaneous immune checkpoint inhibitors. Upon completion of this activity, participants should be better able to: Describe the rationale for subcutaneous (SC) immune checkpoint inhibitor (ICI) administration in the context of standard care with intravenous...

Mar 24, 202616 min

HER2 in Focus: Guiding Bladder Cancer Treatment Personalization in the Era of Antibody-Drug Conjugates

Please visit answersincme.com/860/101393625-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Yohann Loriot, MD, PhD and Andrea Necchi, MD. In this activity, experts in genitourinary cancers examine evidence-based strategies for integrating HER2 biomarker testing and HER2-directed antibody-drug conjugates into personalized, multidisciplinary care for advanced bladder cancer. Upon completion of this activity, participants ...

Mar 20, 20261 hr 8 min

Contextualizing the Data for Novel First-Line HER2+ mBC Maintenance Therapies: How Might the Treatment Paradigm Change?

Please visit answersincme.com/860/100850799-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Otto Metzger, MD. In this activity, experts in breast cancer discuss the clinical implications of recent data on first-line maintenance strategies in HER2-positive metastatic breast cancer. Upon completion of this activity, participants should be better able to: Summarize the latest evid...

Mar 20, 202626 min

Bridging Evidence and Practice: Updates on HER2-Targeted ADCs for Gastric/GEJ Adenocarcinoma

Please visit answersincme.com/HAC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Kohei Shitara, MD, PhD. In this activity, an expert in gastrointestinal oncology discusses the latest data for the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma. Upon completion of this activity, participants should be better able to: Discuss the latest efficacy and safety data for HER2-directed antibody-drug conjugat...

Mar 18, 202617 min

Facing Therapeutic Resistance to Maintenance Therapy: The Need for Novel Strategies in HER2+ mBC

Please visit answersincme.com/860/100850799-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Sara A. Hurvitz, MD, FACP. In this activity, experts in breast cancer discuss the evolving standard-of-care and emerging first-line maintenance strategies in HER2-positive metastatic breast cancer. Upon completion of this activity, participants should be better able to: Review the ration...

Mar 13, 202625 min

Vasomotor Symptoms Due to Breast Cancer Treatment: The Emergence of Neurokinin Receptor Antagonists

Please visit answersincme.com/DZU860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michelle Jacobson, MD, MHSc, FRCSC, MSCP; Nadia Harbeck, MD, PhD; and Renate Haidinger. In this activity, experts in breast cancer and menopause discuss the burden of vasomotor symptoms (VMS) due to breast cancer treatment and the emerging role of neurokinin (NK) receptor antagonists in alleviating these symptoms in practice, with insights fro...

Mar 06, 202628 min

RAS(ON) Inhibition: On the Path to Overcoming Therapeutic Resistance and Targeting More Variants in KRAS-Mutated NSCLC

Please visit answersincme.com/860/120773-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alex Spira, MD, PhD, FASCO; and Kathryn C. Arbour, MD. In this activity "In this activity, experts in oncology discuss the evolving role of RAS(ON) inhibitors in shaping future treatment strategies for patients with KRAS-mutated non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able ...

Mar 02, 20261 hr 2 min

Rethinking HER2 Status: Practical Testing Considerations for HER2-Low and -Ultralow Advanced Breast Cancer

Please visit answersincme.com/CZS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Giuseppe Curigliano, MD, PhD. In this activity, an expert in oncology discusses the differentiation of patients with HER2-low/ultralow/negative advanced breast cancer and treatment with antibody-drug conjugates. Upon completion of this activity, participants should be better able to: Differentiate HER2-low, -ultralow, and -negative advanced br...

Feb 19, 202621 min

Breaking Old Habits in Lung Cancer Detection: Expanding Screening Efforts Among At-Risk Populations

Please visit answersincme.com/RCG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Raymond Osarogiagbon, MD, MBBS, FACP, FASCO; and Michael Gieske, MD. In this activity, experts in lung cancer discuss practical strategies for lung cancer screening. Upon completion of this activity, participants should be better able to: Recognize barriers to achieving lung cancer screening for eligible patients; Identify patients at high ris...

Feb 10, 202618 min

Getting Practical About Optimizing Management of Stage II and III NSCLC: Expert Guidance to Elevate Care

Please visit answersincme.com/860/97150451-replay4 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; Kristin Higgins, MD and Nicolas Girard, MD, PhD. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss real-world learner questions to provide evidence-based strategies for applying immunotherapy in resectable and unresectable NSCLC, with practical guidance tailored to everyday cli...

Feb 09, 202635 min
For the best experience, listen in Metacast app for iOS or Android